Evidence & regulatory context
- Mechanism
- Recombinant silk-elastin-like protein-polymer hydrogel; biomaterial.
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MixedWoundGenetically diabetic mice (C57BLKS/J Iar+Lepr db/+Lepr db); Hartley (std:Hartley) guinea pigsFemalen = 120 female diabetic mice (n = 30 per group across silk-elas…Topical, implanted into the wound and covered with polyurethane film56 microlitres per animal of 20% (w/v) aqueous silk-elastin…Applied immediately after wound creation
Model: Full-thickness skin defect 12 mm in diameter on the back of diabetic mice (chronic ulcer model) and 8 mm full-thickness defect within a 10 mm tattooed ring on the back of healthy guinea pigs (acute ulcer model)
In diabetic mice at 14 days the silk-elastin group showed a significantly higher epithelialisation rate than all other groups (about 1.5-fold) and a significantly larger granulation tissue area than control and Intrasite gel groups; at 21 days epithelialisation remained higher than control and Intr…
Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.